[Loa loa meningoencephalitis secondary to treatment with mebendazol].
Moliner
Joaquín Velilla
JV
Valverde
Antonio Giménez
AG
Sorolla
José Miguel Franco
JM
D000293:Adolescent; D015766:Albendazole / Q000627:therapeutic use; D000818:Animals; D000871:Anthelmintics / Q000009:adverse effects* / Q000627:therapeutic use; D001925:Brain Damage, Chronic / Q000209:etiology; D020809:Central Nervous System Helminthiasis / Q000209:etiology / Q000469:parasitology* / Q000628:therapy; D002555:Cerebrospinal Fluid / Q000469:parasitology*; D002585:Cesarean Section; D003131:Combined Modality Therapy; D004049:Diethylcarbamazine / Q000627:therapeutic use; D005260:Female; D016701:Guinea / Q000453:epidemiology; D006801:Humans; D008118:Loiasis / Q000150:complications* / Q000188:drug therapy*; D016778:Malaria, Falciparum / Q000150:complications; D008463:Mebendazole / Q000009:adverse effects* / Q000627:therapeutic use; D008590:Meningoencephalitis / Q000209:etiology / Q000469:parasitology* / Q000517:prevention & control / Q000628:therapy; D008842:Microfilariae; D018512:Parasitemia / Q000150:complications / Q000188:drug therapy* / Q000469:parasitology; D010956:Plasmapheresis; D011183:Postoperative Complications / Q000469:parasitology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000469:parasitology*; D011644:Puerperal Disorders / Q000209:etiology / Q000469:parasitology; D013030:Spain
D000871:Anthelmintics; D008463:Mebendazole; D015766:Albendazole; D004049:Diethylcarbamazine